Menu Search
Equities

CANbridge Pharmaceuticals Inc

1228:HKG.HS

CANbridge Pharmaceuticals Inc

Actions
  • Price (HKD)0.245
  • Today's Change0.005 / 2.08%
  • Shares traded20.00k
  • 1 Year change-82.62%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 05:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.

  • Revenue in HKD (TTM)113.83m
  • Net income in HKD-443.90m
  • Incorporated2017
  • Employees93.00
  • Location
    CANbridge Pharmaceuticals IncRongchuang Roadchaoyang DistrictSuite 301, 3f, Timeloit No.17SUZHOU 02142-1530ChinaCHN
  • Phone+86 1 084148018
  • Fax+86 1 084148017
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.